EGFR as a prognostic marker for gastric cancer

World Journal of Surgery

Volumn 32, Issue 6, 2008, Pages 1225-1226

  Liakakos, Theodore ^a   Xeropotamos, Nikolaos ^a   Ziogas, Dimosthenis ^a   Roukos, Dimitrios ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LETTER; MEDICAL DECISION MAKING; PROGNOSIS; STOMACH CANCER;

ADENOCARCINOMA; HUMANS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 43949136422     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-9434-3     Document Type: Letter

References (29)

1. Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98-107
2. Jemal A, Siegel R, Ward E et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
3. Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80:16-24
4. Siewert JR, Bottcher K, Stein HJ et al. (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228:449-461
5. Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59-62
6. Sano T (2007) Tailoring treatments for curable gastric cancer. Br J Surg 94:263-264
7. Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127-129
8. Roukos DH, Hottenrott C, Encke A et al. (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3:115-125
9. Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727-730
10. Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253-255
11. Macdonald JS, Smalley SR, Benedetti J et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
12. Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220-221
13. Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
14. Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691-2695
15. Galizia G, Lieto E, Orditura M et al. (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31:1458-1468
16. Friedman A, Perrimon N (2007) Genetic screening for signal transduction in the era of network biology. Cell 128:225-231
17. Greenman C, Stephens P, Smith R et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158
18. Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6:308-312
19. Valverde CM, Macarulla T, Casado E et al. (2006) Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol 59:128-138
20. Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29-39
21. Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197, authors reply 198
22. Briasoulis E, Liakakos T, Dova L et al. (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931-939
23. Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9:607-609
24. Roukos DH, Agnanti NJ, Paraskevaidis E et al. (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9:941-943
25. Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rationale of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030-1034
26. Fatouros M, Baltoyiannis G, Roukos DH (2007) The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol doi: 10.1245/s10434-007-9612-4, [Epub ahead of print]
27. Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578-590
28. Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555-1556; author reply 1556
29. Liakakos T, Roukos DH (in press) More controversy than ever - Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol doi: 10.1245/s10434-007-9798-5